156-83-2Relevant articles and documents
Synthesis and anticancer activity of some pyrimidine derivatives with aryl urea moieties as apoptosis-inducing agents
Bakar-Ates, Filiz,Ozmen, Nuri,Kilic-Kurt, Zühal
, (2020)
A new series of pyrimidine derivatives containing aryl urea moieties was designed and synthesized. The anticancer activities of all compounds were evaluated in vitro against colon and prostat cancer cell lines by MTT assay. Among these compounds, 4b exhibited the highest cytotoxic activity against SW480 cancer cell line with IC50 value of 11.08 μM. Mechanistic studies showed that compound 4b arrested cell cycle at G2/M phase and induced apoptosis through upregulating Bax, Ikb-α and cleaved PARP and downregulating Bcl-2 expression levels. Moreover, compound 4b induced loss of mitochondrial membrane potential in SW480 cells. These results suggest that pyrimidine with urea moieties could be a template for designing new anticancer agents.
Synthesis of 2,4-diaminopyrimidine core-based derivatives and biological evaluation of their anti-tubercular activities
Ouyang, Yifan,Yang, Hao,Zhang, Peng,Wang, Yu,Kaur, Sargit,Zhu, Xuanli,Wang, Zhe,Sun, Yutong,Hong, Wei,Ngeow, Yun Fong,Wang, Hao
, (2017)
Tuberculosis (TB) is a chronic, potentially fatal disease caused by Mycobacterium tuberculosis (Mtb). The dihyrofolate reductase in Mtb (mt-DHFR) is believed to be an important drug target in anti-TB drug development. This enzyme contains a glycerol (GOL) binding site, which is assumed to be a useful site to improve the selectivity towards human dihyrofolate reductase (h-DHFR). There have been previous attempts to design drugs targeting the GOL binding site, but the designed compounds contain a hydrophilic group, which may prevent the compounds from crossing the cell wall of Mtb to function at the whole cell level. In the current study, we designed and synthesized a series of mt-DHFR inhibitors that contain a 2,4-diaminopyrimidine core with side chains to occupy the glycerol binding site with proper hydrophilicity for cell entry, and tested their anti-tubercular activity against Mtb H37Ra. Among them, compound 16l showed a good anti-TB activity (MIC = 6.25 μg/mL) with a significant selectivity against vero cells. In the molecular simulations performed to understand the binding poses of the compounds, it was noticed that only side chains of a certain size can occupy the glycerol binding site. In summary, the novel synthesized compounds with appropriate side chains, hydrophobicity and selectivity could be important lead compounds for future optimization towards the development of future anti-TB drugs that can be used as monotherapy or in combination with other anti-TB drugs or antibiotics. These compounds can also provide much information for further studies on mt-DHFR. However, the enzyme target of the compounds still needs to be confirmed by pure mt-DHFR binding assays.
Method for synthesizing 2,4-diamino-6-chloropyrimidine
-
Paragraph 0036; 0037, (2018/04/21)
The invention discloses a method for synthesizing 2,4-diamino-6-chloropyrimidine. According to the method, methyl cyanoacetate, guanidine nitrate and sodium methoxide serve as raw materials to react with one another to obtain 2,4-diamino-6-hydroxypyrimidine, and then 2,4-diamino-6-hydroxypyrimidine is chloridized with POCl3 in the presence of triethylamine to obtain 2,4-diamino-6-chloropyrimidine.Compared with the prior art, the situation that the whole reactant is neutralized to generate and precipitate a large amount of phosphate is avoided, the product purity is improved, the product yieldis increased, the situation that a solvent is used for refining DACP is avoided, the process is greatly simplified, the cost is reduced, the yield is increased, and the method has the advantages of being high in yield, easy to operate and high in safety and is a very effective process suitable for industrialized mass production.
ARYL PYRIMIDINE DERIVATIVES
-
, (2008/06/13)
The disclosed pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, in particular use as selective 5HT 2B-antagonists. The invention is also directed to formulations and methods for treatment.
ARYL PYRIMIDINE DERIVATIVES
-
, (2008/06/13)
The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT 2B-antagonists.
ARYL PYRIMIDINE DERIVATIVES AND USES THEREOF
-
, (2008/06/13)
The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT 2B-antagonists. The 5-HT 2B antagonist is a compound of the formula: STR1 wherein: R. sup.1 is hydrogen, alkyl, lower alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl,--NR 6 R. sup.7,--CO 2 R 8,--O(CH 2) n R 9, or lower alkyl optionally substituted with hydroxy, alkoxy, halo, or aryl; in which n is 1, 2, or 3;R 6 and R 7 are hydrogen or lower alkyl; R 8 is hydrogen or lower alkyl; andR 9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;R. sup.2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl; R 3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;R 4 is hydrogen, lower alkyl, cycloalkyl, alkenyl, acyl, amino, amido, aryl,--(CH 2) m NR. sup.10 R 11, or lower alkyl optionally substituted by amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, aryl, lower alkoxy, amido, alkoxy carbonyl, tetrahydrofuran-2-yl, hydroxyalkoxy, or sulfonamido;in whichR 10 and R. sup.11 are hydrogen or lower alkyl; andR 5 is hydrogen or lower alkyl; provided that: (i) when R 3 is naphthyl, indol-1-yl, or 2,3-dihydroindol-1-yl, and R 2, R 4 and R 5 are all hydrogen, R. sup.1 is not methyl; (ii) when R 3 is phenyl or naphthyl, R 1 is not--NR 6 R 7 ;(iii) when R 3 is phenyl, R 2 is not lower alkoxy, and R 1 and R 2 are not halo;(iv) when R 3 is phenyl and R 1 is H, R 2 is not methyl; and (v) when R 3 is 1,2,3,4-tetrahydroquinolinyl, R 4 and R. sup.5 are hydrogen;or a pharmaceutically acceptable salt or N-oxide thereof.
A process for the preparation of 2,4-diamino-6-(1-piperidinyl)-pyrimidine N-oxide
-
, (2008/06/13)
A process for the preparation of 2,4-diamino-6-(1-piperidinyl)-pyrimidine N-oxide which process consists in reacting 6-chloro 2,4-diamino-pyrimidine of formula II with the monoperphthalic acid magnesium salt, of formula VI to obtain 2,6-diamino-4-chloro-pyrimidine N-oxide of formula VII which is reacted with piperidine to give desired compound I.
Synthesis of Some Substituted Guanidinopyrimidines and their Structural Assignment by 13C and 1H NMR
Ladd, David L.
, p. 917 - 921 (2007/10/02)
A series of substituted 2- and 4-guanidinopyrimidines were prepared by reaction of halopyrimidines with guanidine; alkylamino and amino substituents were introduced by subsequent halogen replacement by primary amines or ammonia or the catalytic reduction of nitro groups.Structural assignments were made on the basis of 13C and 1H nmr.A guanidinopteridine and a bispyrimidinylguanidine were also synthesized.Some unsuccessful reaction illustrated the low nucleophilic reactivity and thermal instability of the guanidine group.
